论文部分内容阅读
目的探讨红豆杉醇提物作为H3N2流感病毒灭活疫苗佐剂对小鼠的免疫原性及安全性。方法将ICR小鼠随机分为5组,每组7只,醇提红豆杉佐剂组:含血凝素1.2μg,红豆杉醇提物0.2 mg;水提红豆杉佐剂组:含血凝素1.2μg,红豆杉水提物0.2 mg[3];铝佐剂对照组:含氢氧化铝0.2 mg,血凝素1.2μg;疫苗对照组:含血凝素1.2μg;空白对照组:注射生理盐水0.2 ml。分别于0、21 d经腿部肌肉注射免疫2次,每次0.2 ml/只,初免后每隔7 d采血,收集血清,检测血凝抑制(HI)抗体效价,于初免后1、21、70 d观察各组小鼠的体重变化,并测定红豆杉醇提物的小鼠半数致死量(LD50)。结果醇提红豆杉佐剂组各时间点的小鼠血清HI抗体效价均高于疫苗对照组,在28 d时,含佐剂疫苗组的抗体效价均高于单独疫苗组,醇提红豆杉佐剂组的抗体产生先于铝佐剂对照组;各组小鼠体重增长差异无统计学意义(P>0.05);红豆杉醇提物的LD50值为577.93 mg/kg。结论红豆杉醇提物作为流感疫苗佐剂具有良好的安全性及有效性,有望成为流感灭活疫苗的新型免疫佐剂。
Objective To investigate the immunogenicity and safety of alcohol extract of Taxus chinensis as adjuvant of H3N2 influenza virus inactivated vaccine against mice. Methods ICR mice were randomly divided into 5 groups with 7 mice in each group. The animals were treated with Taxus chinensis adjuvant: 1.2μg hemagglutinin and 0.2 mg alcohol extract of Taxus chinensis. 1.2μg of calluses and 0.2 mg of aqueous extract of Taxus chinensis [3]; aluminum adjuvant control group: 0.2 mg of aluminum hydroxide and 1.2μg of hemagglutinin; Vaccine control group: Hemagglutinin 1.2μg; Blank control group: Saline 0.2 ml. The mice were intramuscularly immunized twice a day for 0.2 ml once daily at 0 and 21 days, and blood was collected every 7 days after initial immunization. The serum was collected and the titer of HI was tested. After initial immunization, The changes of body weight of mice in each group were observed on day 21 and day 70, and the LD50 of the extract of Taxus chinensis was determined. Results The serum HI antibody titers of mice in the Taxus chinensis at various time points were higher than that of the vaccine control group. At 28 days, the antibody titer of the adjuvanted vaccine group was higher than that of the vaccine alone group. Antibody production of the cedar adjuvant group was prior to that of the aluminum adjuvant control group. There was no significant difference in weight gain between the groups (P> 0.05). The LD50 value of the taxol extract was 577.93 mg / kg. Conclusion The extract of Taxus chinensis has good safety and efficacy as an adjuvant for influenza vaccine and is expected to become a novel immunological adjuvant for influenza inactivated vaccine.